Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy are a standard of care in hormone receptor positive, HER2 negative metastatic breast cancer. Palbociclib(1-5), ribociclib(6-11) and abemaciclib(12-15) have all been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency among other regulatory bodies. CDK4/6i can be used in combination with aromatase inhibitors (AI) or with fulvestrant. Multiple randomized trials(1-3, 9-12, 15) support the registration of CDK4/6i and both trial-level(16) and individual patient data(17) meta-analyses confirm the benefit from this group of drugs.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research